You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2025

Claims for Patent: 11,918,628

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,918,628

Title:	Controlled-release PTH compound
Abstract:	The present invention relates to a controlled-release parathyroid hormone (PTH) compound in which PTH(1-34) is reversibly conjugated to a branched polyethylene glycol. The invention further relates to a pharmaceutical composition of the compound. The compound or pharmaceutical composition is useful for treatment, control, delay or prevention of a condition that can be treated, controlled, delayed or prevented with PTH.
Inventor(s):	Kennett Sprogøe, Felix Cleemann, Guillaume Maitro, Mathias Krusch, Thomas Wegge, Joachim Zettler
Assignee:	Ascendis Pharma Bone Diseases AS
Application Number:	US18/355,223
Patent Claims:	1. A parathyroid hormone (PTH) conjugate of formula: or a pharmaceutically acceptable salt thereof, wherein the unmarked dashed line indicates the attachment by an amide bond to the N-terminal nitrogen of a PTH moiety, the amino acid sequence of which consists of the sequence of SEQ ID NO:51; and the dashed line marked with the asterisk indicates attachment to a moiety wherein m and p are independently an integer ranging from and including 150 to 1000. 2. The PTH conjugate or pharmaceutically acceptable salt thereof of claim 1, wherein the moiety has a molecular weight of about 15-80 kDa. 3. The PTH conjugate or pharmaceutically acceptable salt thereof of claim 1, wherein m and p are the same integer. 4. A pharmaceutical composition comprising the PTH conjugate or pharmaceutically acceptable salt thereof of claim 1 and at least one excipient. 5. The pharmaceutical composition of claim 4, wherein the pharmaceutical composition has a pH of 4-6. 6. A liquid pharmaceutical composition comprising a parathyroid hormone (PTH) conjugate of formula: or a pharmaceutically acceptable salt thereof, and a solvent, wherein the unmarked dashed line indicates the attachment by an amide bond to the N-terminal nitrogen of a PTH moiety, the amino acid sequence of which consists of the sequence of SEQ ID NO:51; and the dashed line marked with the asterisk indicates attachment to a moiety wherein m and p are independently an integer ranging from and including 150 to 1000. 7. The liquid pharmaceutical composition of claim 6, wherein the moiety has a molecular weight of about 15-80 kDa. 8. The liquid pharmaceutical composition of claim 7, wherein m and p are the same integer. 9. The liquid pharmaceutical composition of claim 7, wherein the solvent is water.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.